clinical trial · NCT03319849
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
Macular Telangiectasia Type 2NT-501Sham
brief summary
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
started
Jan 22, 2018
primary completion
Aug 31, 2022
completion
Sep 23, 2022
last updated
Sep 24, 2024
detailed description
Phase 3, prospective, multicenter, masked, sham-controlled study with the overall study objective to evaluate the efficacy and safety of NT-501 for the treatment of MacTel. Secondary objective was to evaluate the safety of NT-501 in participants with MacTel. This was a multicenter study conducted at 20 study centers in the United States, Australia, Germany, and the United Kingdom.
official title
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol